Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | nuclear factor, erythroid 2-like 2 | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Influenza A virus | Nonstructural protein 1 | Starlite/ChEMBL | No references |
Homo sapiens | TAR DNA binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Mycobacterium tuberculosis | Hypothetical protein | Nonstructural protein 1 | 230 aa | 202 aa | 23.8 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0858 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0043 | 0.1522 | 0.2624 |
Schistosoma mansoni | tar DNA-binding protein | 0.0127 | 0.5803 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.0858 | 0.0599 |
Loa Loa (eye worm) | RNA binding protein | 0.0127 | 0.5803 | 0.5684 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0127 | 0.5803 | 0.5684 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.2379 | 0.2163 |
Onchocerca volvulus | Rap guanine nucleotide exchange factor 1 homolog | 0.0209 | 1 | 0.5 |
Brugia malayi | RNA binding protein | 0.0127 | 0.5803 | 0.5684 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0276 | 0.0475 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0276 | 0.0475 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.0858 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0127 | 0.5803 | 1 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.2379 | 0.2163 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0276 | 0.0475 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.1522 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0127 | 0.5803 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0276 | 0.0475 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0858 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0858 | 0.5 |
Loa Loa (eye worm) | TAR-binding protein | 0.0127 | 0.5803 | 0.5684 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0858 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0127 | 0.5803 | 1 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0276 | 0.0475 |
Echinococcus granulosus | GPCR family 2 | 0.0019 | 0.0276 | 0.0475 |
Echinococcus multilocularis | tar DNA binding protein | 0.0127 | 0.5803 | 1 |
Brugia malayi | hypothetical protein | 0.002 | 0.0307 | 0.0032 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.1522 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0127 | 0.5803 | 1 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.1405 | 0.1162 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.1522 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.0858 | 0.5 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.2379 | 0.2163 |
Echinococcus multilocularis | GPCR, family 2 | 0.0019 | 0.0276 | 0.0475 |
Brugia malayi | TAR-binding protein | 0.0127 | 0.5803 | 0.5684 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0276 | 0.0475 |
Brugia malayi | hypothetical protein | 0.003 | 0.0858 | 0.0599 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.2379 | 0.2163 |
Brugia malayi | hypothetical protein | 0.0043 | 0.1522 | 0.1282 |
Entamoeba histolytica | hypothetical protein | 0.0043 | 0.1522 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0043 | 0.1522 | 0.2624 |
Schistosoma mansoni | tar DNA-binding protein | 0.0127 | 0.5803 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1405 | 0.1162 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0043 | 0.1522 | 0.2624 |
Loa Loa (eye worm) | hypothetical protein | 0.0209 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0276 | 0.0475 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.1405 | 0.2422 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.0858 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0127 | 0.5803 | 0.5684 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.0858 | 0.5 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0043 | 0.1522 | 0.2624 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0276 | 0.0475 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.7783 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.9953 uM | PubChem BioAssay. qHTS of TDP-43 Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 4.1475 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 9.2 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | = 10 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Influenza NS1 Protein Function. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 12.5893 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 20.5878 uM | PUBCHEM_BIOASSAY: qHTS screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493107, AID493125] | ChEMBL. | No reference |
Potency (functional) | 26.8545 uM | PUBCHEM_BIOASSAY: qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for miR-21 project). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID2288, AID2289, AID2598, AID411] | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 56.2341 uM | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Kappa. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588638] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.